These innovative molecules represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose levels. https://elodieigza529112.bloguetechno.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-75337331